Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner -- Ignore unavailable to you. Want to Upgrade?

To: CYBERKEN who wrote (255)	11/23/1997 1:03:00 PM
From: biopicker	Respond to of 353

As an aside, on Thursday, after the close, Arris announced that Ann F. Welton, PhD, aged 50, will join the company as Vice President, Biology & PreClinical Sciences, in early 1998. Since 1977, Welton has been a Research Scientist with Hoffmann-LaRoche, Inc., most recently serving as Vice President of Non-Clinical Development within international R&D, with management responsibility for over 400 researchers at the Nutley site. Put one and one together, and you get a very experienced individual with very big responsibilities leaving a major drug company to join a deveopment-stage company. This can only indicate the degree of confidence Welton has in what Walker is doing at Arris. I value that kind of opinion and statement must more than a lot of the research that comes out of Wall Street. Cheers!